1. Introduction {#sec1}
===============

*Acinetobacter baumannii* is a gram-negative, strictly aerobic, nonfermenting coccobacillus belonging to the Moraxellaceae family [@bib1]. Species belonging to this genus are opportunistic pathogens with increasing relevance in both community-acquired and nosocomial infections, particularly among patients in intensive care units (ICUs) and high-dependency units (HDUs) [@bib2; @bib3; @bib4; @bib5]. These organisms have been implicated in various infections, including ventilator-associated pneumonia, endocarditis, meningitis, and infections of the skin, soft tissues, urinary tract, and those originating from prosthetic devices [@bib4; @bib6]. *A. baumannii* has been isolated from numerous sources such as soil, water, animals, and humans, while its presence in health care institutions and on environmental surfaces has been extremely difficult to control [@bib6].

Three decades ago, *A. baumannii* infections were effectively treated with traditional antibiotics [@bib7; @bib8]. By contrast, it currently exerts resistance to nearly all major classes of antibiotics, including broad-spectrum penicillins, cephalosporins, carbapenems, most aminoglycosides, fluoroquinolones, chloramphenicol, and tetracyclines. In the past decade, multidrug resistant (MDR) clinical isolates have shown global distribution [@bib3]. Therefore, this pathogen has become a "red-alert" for the following reasons: rapid emergence of resistance, increased incidence, and the worldwide spread of MDR isolates [@bib7]. The rapid spread of MDR strains in nosocomial infections that exhibit resistance to most or all common antibiotics is a troubling evolution [@bib3]. Thus, a study of the antibiotic resistance patterns both in individual hospitals and on countrywide levels may help to clarify the mode of *A. baumannii* antibiotic resistance spread and epidemiology worldwide [@bib9]. The current review was performed to elucidate the mode of antibiotic resistance of *A. baumannii* in Iran.

2. Materials and methods {#sec2}
========================

2.1. Database searches {#sec2.1}
----------------------

Biomedical databases (Scopus, Medline, Web of Science, EBSCO, IranMedex) were searched in order to retrieve all related manuscripts published in English and Persian. The search identified publications of epidemiological studies in order to compile adequate information on *A. baumannii* antimicrobial resistance in Iran. The following key words were used: "*Acinetobacter baumannii* and Iran", "antimicrobial resistance and *Acinetobacter baumannii* and Iran", "antimicrobial resistance and either gram negative bacilli and Iran or Iran", "nosocomial or hospital acquired and Iran" . Study publications were obtained through PubMed, MEDLINE, and IranMedex database searches. Also, references cited within these articles were used to find additional relevant articles. In this review, *A. baumannii* susceptibility breakpoints based on Clinical Laboratory Standards Institute (CLSI)-relevant antibiotics were primarily those listed by the World Health Organization Recommended Surveillance Standards.

2.2. Study settings {#sec2.2}
-------------------

From the first 87 papers, we identified a total of 36 that were written in English and considered to be eligible for inclusion in this review. The selected papers were published between 2008 and September 2014. We categorized studies on the basis of sample collection year, between 2001 and 2013; some papers collect samples during different years ([Table 1](#tbl1){ref-type="table"}). Two studies were performed in three regions of Iran, including central, north, and south. Twenty-two studies were performed north of Iran, with 18 in Tehran (capital of Iran). Two studies occurred in the south of Iran, three in the west, and three in the east. Although the studies used various methods, they were all approved by the CLSI and the National Committee for Clinical Laboratory Standards (NCCLS) and, therefore, suitable for trend analysis.

2.3. Microbiological methods {#sec2.3}
----------------------------

Clinical specimens in studies were collected from hospitalized patients with different disease and various sampling. Twenty of the studies obtained data from various clinical specimens, including blood, cerebrospinal fluid, urine, sputum, and respiratory tract samples. Data from eight studies were obtained from patients with burn wounds and seven from hospitalized patients in ICUs. Antibiotic susceptibility testing methodologies were declared in all studies, all of which were performed according to the CLSI breakpoints. Twenty-six studies used the Kirby-Bauer disk diffusion method, nine used the E-test, and two used broth microdilution. To identify resistance genes, 25 of the studies used one or more polymerase chain reaction-based molecular methods.

3. Results {#sec3}
==========

3.1. Phenotypic resistance rates for different antibiotics {#sec3.1}
----------------------------------------------------------

The susceptibility data for 3049 *A. baumannii* isolates are shown in [Table 2](#tbl2){ref-type="table"}. These data reflect the 12-year period from 2001 to 2013 of sampling time in the studies identified. The data demonstrate that, with the exception of carbapenems, lipopeptides, and aminoglycosides, there was a high rate of resistance to antimicrobial groups during the initial time point of this study (2001--2007). Also, the resistance rate was increased in one group of these three antimicrobial groups from 2010 to 2013. In particular, there was an increase in resistance to carbapenems (imipenem and meropenem) from 2010--2011 and 2012--2013, whereas no significant change in the resistance rate to other two antimicrobial groups (lipopeptides and aminoglycosides) during the study time was observed, although we did observe certain trends in amikacin (aminoglycoside group antibiotic) between 2011--2012 and 2012--2013.

There are data regarding resistance to penicillins from 2001 to 2011. There was a remarkable increase in piperacillin resistance (from 63.9% in 2001--2007 to 93.4% in 2010--2011). The resistance rate to the β-lactam/β-lactamase combination group was high early in the study, with no substantial change to the study endpoint. The highest level of antimicrobial resistance throughout the study was noted among the cephems group (\>90%), including ceftazidime, cefepime, cefotaxime, and ceftriaxone. Resistance to carbapenems was low at the study start point (51.1% imipenem, 64.3% meropenem) and increased by the end of the study (76.5% imipenem, 81.5% meropenem), thus demonstrating the most drastic increase in resistance rate. A low level of resistance at the starting point was also observed for lipopeptides (polymyxin B and colistin), with no significant trends as the study progressed. The resistance rate to aminoglycosides was low, with the exception of amikacin (from 58.4% in 2001--2007 to 95% in 2012--2013). At the beginning of the study, there were no data for tetracyclines, whereas there was a high level of resistance to this group at the study endpoint. Resistance to fluoroquinolones was high during the study period with no remarkable pattern change. Finally, an increased resistance rate to folate pathway inhibitors, including trimethoprim sulfamethoxazole, was observed (from 76.6% in 2001--2007 to 99% in 2012--September 2014). In summary, these data demonstrate a high resistance rate to all antimicrobial agents except lipopeptides.

3.2. Genotypic resistance rate {#sec3.2}
------------------------------

Genotyping of a total of 1717 *A. baumannii* isolates was performed in 17 studies. [Table 3](#tbl3){ref-type="table"} shows the mechanisms of resistance that were studied for the different antibiotic classes from 2001 to 2013. The genotyping methods in all studies were polymerase chain reaction- and sequence-based. Among the 17 studies, 14, three, three, and one of them were focused on β-lactams, tetracyclines, aminoglycosides, and quinolones, respectively. These genotypic studies demonstrated that isolates harboring resistance genes have increased from 2001 to 2013, which is most remarkable for carbapenem.

3.3. Distribution of multidrug resistance {#sec3.3}
-----------------------------------------

By definition, MDR *A. baumannii* isolates are resistant to three or more agents of different antibiotic classes. In total, seven studies revealed the presence of MDR isolates. Among these seven studies, this analyzed 584 *A. baumannii* isolates, MDR rates ranged from 32.7% to 93%. Chronologically, these rates can be broken down as follows: 2001--2007 (1 study, 50%), 2008--2009 (1 study, 66%), 2009--2010 (1 study, 83%), and 2010--2011 (4 studies, 32.7%, 74.9%, 93%, 94.4%, respectively). In general, the prevalence of MDR increased throughout the duration of the study.

4. Discussion {#sec4}
=============

*A. baumannii* infection has become a critical challenge to health care systems. To become an optimally successful pathogen, an organism must develop antimicrobial resistance. Although there is debate regarding the definitions of "multidrug" and "pandrug" resistance [@bib45], an understanding has been reached in that resistance to all common antimicrobial agents is currently a common problem in health care institutions [@bib46; @bib47]. The emergence of MDR isolates has become a serious problem that has made it difficult to select an empirical antimicrobial for the treatment of *A. baumannii* infections. Therefore, monitoring the antibiotic resistance patterns of this organism over time may provide useful information regarding its treatment policy. This systematic review considered the distribution of antibiotic-resistant *A. baumannii* in CLSI-approved studies published in Iran between 2001 and September 2014.

According to the results, some level of resistance to all antibiotic classes existed in the beginning of our study. However, we revealed that the distribution of antimicrobial resistance to all agents was high at the endpoint, with the exception of the lipopeptides. Currently, the antibiotics of choice for treatment of *A. baumannii* infections include the aminoglycosides, fluoroquinolones, and carbapenems [@bib48]. Thus, it is concerning that our data demonstrate that *A. baumannii* resistance to these agents increased over the time course of this study, with a resistance rate in excess of 90% in 2013. As such, these antibiotics may not be appropriate empirical therapy in many cases. For example, carbapenems are one of the most clinically important classes of antibiotics used against life-threatening *A. baumannii* infections in Iran [@bib10]. Our results showed that this group of antibiotics had low-level resistance in 2001--2007 (51.1% imipenem, 64.3% meropenem), which increased in 2012--2013 (76.5% imipenem, 81.5% meropenem). The data also showed that the most drastic increase in resistance is associated with this antibiotic class, possibly due to its frequency of use in health care units. This is an alarming finding that strongly suggests the possibility of treatment failures in life-threatening *A. baumannii* infections due to carbapenem-resistance strains.

As mentioned previously, our data show that resistance to lipopeptides is lower compared with that of other antimicrobial groups. One of the antibiotics of this class is polymyxin B, which, despite previous concerns regarding its toxicity, has been implemented in treatment more frequently [@bib49]. Another lipopeptide antibiotic is colistin, which has proven effective in the treatment of wound, urinary tract, and bloodstream infections [@bib50], although its nephrotoxicity is a disadvantage to its use [@bib51]. Although use of this antibiotic class has limitations due to toxicity, they are often used for the treatment of life-threatening infections.

In addition to an increase in antibiotic-resistant *A. baumannii* strains from 2001 to 2013, the prevalence of MDR strains also increased (from 50% in 2001--2007 to 74% in 2010--2011), with a mean prevalence of 71.2%. Treatment of MDR strains is usually difficult, thus creating critical challenges for health care consultants [@bib52; @bib53]. The antibiotic choice for the treatment of MDR *A. baumannii* infections is also limited and includes the lipopeptides, [@bib52; @bib54] which the results of this study suggest is the best class of antibiotics to use for MDR because of the lower prevalence of resistance.

In summary, our results demonstrate the need for effective surveillance of antimicrobial resistance in *A. baumannii* in Iran and suggest that it is essential to use antibiotics with the most caution to prevent the emergence of drug-resistant strains. Furthermore, these findings indicate that the prevalence of antibiotic-resistant *A. baumannii* is high in Iran, especially for the antibiotics of choice. This is an emerging concern to public health, particularly in the clinical management of persons with life-threatening *A. baumannii* infections. We strongly suggest the implementation of a countrywide surveillance system. This would facilitate the active monitoring of resistance frequency and distinguish antibiotic resistance trends and prevalence, all of which would be effective tools in antibiotic treatment programs.
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###### 

Characteristic of *Acinetobacter baumannii* antimicrobial resistance studies in Iran.

  Year of publication (Refs)                                                                                                                                                                          Year of sample collecting   No. of studies   Total samples   Location of Iran (No. of studies)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------------- --------------- ----------------------------------------------------
  2008 [@bib10], 2010 [@bib11], 2011 [@bib12], 2014 [@bib13]                                                                                                                                          2001--2007                  4                383             Capital (4)
  2011 [@bib14], 2011 [@bib15]                                                                                                                                                                        2007--2008                  2                275             Capital (1), South (1)
  2010 [@bib16], 2010 [@bib17], 2011 [@bib14], 2011 [@bib18], 2011 [@bib12], 2012 [@bib19], 2012 [@bib20], 2013 [@bib21]                                                                              2008--2009                  8                680             Capital (1),North (3),West (2),South (1), East (1)
  2011 [@bib22], 2012 [@bib23], 2013 [@bib24]                                                                                                                                                         2009--2010                  3                276             Capital (3)
  2012 [@bib25], 2012 [@bib26], 2013 [@bib27], 2013 [@bib28], 2013 [@bib29], 2013 [@bib30], 2013 [@bib31], 2013 [@bib32], 2013 [@bib33], 2013 [@bib34], 2014 [@bib35], 2014 [@bib36], 2014 [@bib37]   2010--2011                  12               970             Capital (6),North (4),East (1),West (1)
  2013 [@bib30], 2013 [@bib32], 2013 [@bib38], 2013 [@bib39], 2014 [@bib13], 2014 [@bib40]                                                                                                            2011--2012                  6                525             Capital (5), East (1)
  2013 [@bib41], 2013 [@bib42], 2014 [@bib43], 2014 [@bib44]                                                                                                                                          2012--Sep 2014              4                308             Capital (3), North (1)

###### 

Phenotypic antibiotic resistance rates in *Acinetobacter baumannii* isolate from Iran.

  Antibiotic agents   Mean resistance rate (%) in different studies                                         
  ------------------- ----------------------------------------------- ------ ------- ------- ------- ------ ------
  PIP                 69.9                                            88.2   93.75   98      93.4    ---    ---
  MZ                  ---                                             ---    ---     ---     81.7    ---    ---
  TIC                 100                                             ---    100     ---     94      ---    ---
  SAM                 83.3                                            27.8   63.5    48.39   33.7    ---    77.5
  TZP                 52.9                                            35.3   88.6    71.5    97.3    82.5   70
  TIM                 100                                             ---    82.6    ---     94      80     ---
  CAZ                 93.5                                            90.7   92      93      92.6    ---    97
  FEP                 ---                                             94.1   89      96.6    88.6    ---    97
  CTX                 95                                              100    94      99      96.1    98     97
  CRO                 89.1                                            100    93.6    97.3    95.6    ---    97.5
  IPM                 51.1                                            32     57.75   52.4    81.9    80.5   76.5
  MEM                 64.3                                            27.8   59.25   72      85.2    81.5   81.5
  PB                  8.8                                             ---    16      3       13.5    3      9.5
  CST                 ---                                             1.3    19      12      9.3     ---    16
  GEN                 76.85                                           81.9   83.75   40.6    82.9    63     78.5
  TOB                 63.2                                            39.2   ---     28      60.9    56     70
  AMK                 58.4                                            79.4   82.7    69.5    75      89.5   95
  NET                 80.5                                            ---    ---     ---     69.6    ---    ---
  TET                 ---                                             ---    ---     34.78   83.82   51     56
  DOX                 ---                                             ---    ---     ---     25      ---    42.9
  MIN                 ---                                             ---    ---     ---     25.6    ---    34
  CIP                 83.9                                            67.6   83.75   92      85.2    97     72
  LVX                 83.3                                            ---    81.75   ---     81.25   ---    99
  GAT                 ---                                             ---    ---     ---     43.3    ---    ---
  SXT                 76.6                                            82.4   87.3    ---     94.3    ---    99

AMK = amikacin; CAZ = ceftazidime; CIP = ciprofloxacin; CRO = ceftriaxone; CST = colistin; CTX = cefotaxime; DOX = doxycycline; FEP = cefepime; GAT = gatifloxacin; GEN = gentamicin; IPM = imipenem; LVX = levofloxacin; MEM = meropenem; MIN = minocycline; MZ = mezlocilli; NET = netilmicin; PB = polymyxin B; PIP = piperacillin; SAM = ampicillin/sulbactam; SXT = trimethoprim/sulfamethoxazole; TET = tetracycline; TIC = ticarcillin; TIM = ticarcillin/clavulanic acid; TOB = tobramycin; TZP = piperacillin/tazobactam.

###### 

Genotypic resistance rate in *Acinetobacter baumannii* isolate from Iran.

  Antimicrobial class   Resistance mechanism                 Genes             Mean Resistance rate (%) in different studies   References                                                
  --------------------- ------------------------------------ ----------------- ----------------------------------------------- ------------ ------ ---------- ------------- ---- ------- ----------------------------------------------------------------------------------
  β-lactams             β-lactamases                         PER-1                                                                          51     54.3       27.6               78.03   [@bib21],[@bib27],[@bib23],[@bib45]
                                                             PER-2                                                                          0                                            [@bib21]
                                                             VEB-1                                                                          10                                   39.5    [@bib21],[@bib45]
                                                             TEM-1                                                                                 47.2       13.1                       [@bib27],[@bib23]
                                                             SHV                                                                                   5.6                                   [@bib23]
                                                             IS*Aba*1/ampC                                                                  46                63.1                       [@bib27],[@bib20]
                                                             IS*Aba* 25/ampC                                                                                  7.8                        [@bib27]
                        Carbapenemases                       OXA~-23~ -like    25,                                                          55     24.58,84   30,67,77.9,   80   70.1    [@bib28],[@bib30],[@bib27],[@bib23],[@bib20],[@bib22],[@bib12],[@bib37],[@bib44]
                                                             OXA~-40~ -like                                                                                   17.1,47            35.8    [@bib28],[@bib27],[@bib44]
                                                             OXA~-58~ -like    21.2                                                                                                      [@bib12]
                                                             OXA~-24~ -like    15,                                                                            19.2                       [@bib12],[@bib34]
                                                             OXA~-51~ -like    96                                                                  94         14.4                       [@bib28],[@bib22],[@bib10]
                                                             IMP                                                                            19                                   3.48    [@bib18],[@bib45]
                                                             VIM                                                                            9                                    17.44   [@bib18],[@bib45]
  Tetracyclines         Efflux pump                          Tet A                                                                                            11                         [@bib36]
                                                             Tet B                                                                                            99,86.1            19.4    [@bib36],[@bib37],[@bib44]
  Aminoglycosides       Enzymatic degradation                *aph*(3′)-IIb                                                                                    61.8                       [@bib29]
                                                             *aac*(6′)-Ib                                                                                     60.5               16.4    [@bib29],[@bib44]
                                                             *aph*(3′)-Ia                                                                                     46.1               19.4    [@bib29],[@bib44]
                                                             *ant*(2″)-Ia                                                                                     14.5               56.7    [@bib29],[@bib44]
                                                             *ant*(3″)-Ia                                                                                     10.5                       [@bib29]
                                                             *aph*(3′)-Via                                                                                    9.2,               95.5    [@bib29],[@bib44]
                                                             *aac*(3′)-Ia                                                                                     5.3                32.8    [@bib29],[@bib44]
                                                             *aacC1*                                                                        63.3                                         [@bib16]
                                                             *aadA1*                                                                        41.7                                         [@bib16]
                                                             *aadB*                                                                         3.3                                          [@bib16]
                                                             *aphA6*                                                                        65                                           [@bib16]
                        16s rDNA methyltransferases          *armA*                                                                                                              9       [@bib44]
  Quinolones            DNA gyrase/topoisomerase mutations   *gyrA/parC*                                                                                      100                        [@bib37]
